Clinical trials: Cancer Progression
PD-(L)1, CTLA-4
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer.
- Conditions
- PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab
- Trial name
- NCT07004335
- Testing
- Iparomlimab and Tuvonralimab Injection plus Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Castration-resistant Prostate Cancer
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT02207504
- Testing
- Crizotinib, Enzalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Sickle Cell Disease, Sickle Cell Nephropathy
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2)…
- Trial name
- NCT04335721
- Testing
- Voxelotor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Amyotrophic Lateral Sclerosis
Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)
This is a study in patients with Amyotrophic Lateral Sclerosis (ALS). We will use muscle ultrasound as a tool to try and see if there are changes in muscle size that can find out how fast ALS is progressing.
- Trial name
- NCT00838617
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University
COPD, Disease Progression
Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring
The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations…
- Trial name
- PROMETE (NCT02499068)
- Testing
- Telehealth
- Where
- 5 sites in Spain
- Volunteers
- 237 people
- Sponsor
- Arturo Garcia
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
BLinatumomab and iNKT in Relapsed B-Cell ALL
This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical care blinatumomab in subjects with Philadelphia chromosome-negative…
- Conditions
- B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
- Trial name
- BLINK B-ALL (NCT07869368)
- Testing
- Invariant Natural Killer T Cell Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Small Cell Lung Carcinoma
An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
This exploratory trial aims to determine if it is safe to use radiotherapy and lurbinectedin to treat SCLC with Single-lesion progression after first course treatment.
- Trial name
- NCT06501976
- Testing
- Lurbinectedin, Radiation Therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dentist's Role
Two Preventive Measures on Caries Progression in Mixed Dentition Patients.
Primary Objective: Assessing the clinical effect of SDF and Laser on the prevention of initial caries progression with and without pits and fissure sealants in both permanent and primary molars.
- Trial name
- NCT06119126
- Testing
- SDF1, Diode Laser, Pit Fissure Sealant
- Where
- Egypt
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Metastatic Renal Cell Carcinoma
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.
- Trial name
- TORAVA (NCT00619268)
- Testing
- Temsirolimus, Bevacizumab, Sunitinib
- Where
- 29 sites in France
- Volunteers
- 160 people
- Sponsor
- Centre Leon Berard
Prostate Cancer
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following…
- Trial name
- NCT01204710
- Testing
- Olaratumab, Mitoxantrone, Prednisone
- Where
- 40 sites in Belgium, Czechia and 5 more
- Volunteers
- 123 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Silent Progression Activity Monitoring - SPAM Study
Real-World Data (RWD) exploring the natural history of MS suggested that relapses do not significantly influence the progression of irreversible disability.
- Trial name
- SPAM (NCT05650281)
- Testing
- NO INTERVENTION
- Where
- France
- Volunteers
- 2,230 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Cardiovascular Disease, Chronic Kidney Disease
Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease
Introduction: Chronic kidney disease (CKD) is now an important public health issue. While 0.1% of the population is on dialysis, approximately 4.5% of subjects have renal dysfunction (glomerular filtration rate <60 ml/min/1.73…
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Chronic Renal Disease, Hypertension
- Trial name
- NCT01155128
- Testing
- exercise aerobic
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Federal University of Pelotas
Non-small Cell Lung Cancer
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
This is an open label, non-randomized, sequential, phase I/II trial in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations after progression to Erlotinib. The study will have two parts.
- Trial name
- NCT00503971
- Testing
- Vorinostat plus Erlotinib
- Where
- 8 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Spanish Lung Cancer Group
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Myopia
Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia
The objective of this clinical investigation is to evaluate the efficacy and safety of SAT-001 designed as Software as Medical Device (SaMD) for slowing myopia progression and treatment in pediatric myopia patients.
- Trial name
- NCT06344572
- Testing
- SAT-001, Single vision spectacles
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- S-Alpha Therapeutics, Inc.
Nasopharyngeal Carcinoma, Pathologic Complete Response
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle…
- Conditions
- Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
- Trial name
- NCT06182657
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Breast Cancer
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration…
- Trial name
- ChangHER-SC (NCT01875367)
- Testing
- Trastuzumab Injectable Solution, Trastuzumab Injectable Product, Trastuzumab Injection
- Where
- 27 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Spanish Breast Cancer Research Group
Carcinoma, Non-Small-Cell Lung
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
The primary objective of this trial is to determine the maximum tolerated dose (MTD) and recommended Phase II doses for the combination of BIBW 2992 and cetuximab in patients with non-small cell lung cancer and acquired…
- Trial name
- NCT01090011
- Testing
- Cetuximab, BIBW 2992
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 171 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure…
- Trial name
- NCT00077857
- Testing
- capecitabine (Xeloda®), docetaxel (Taxotere®)
- Where
- 94 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 470 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer.
- Trial name
- MELROSE (NCT03865511)
- Testing
- TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis
- Where
- 17 sites in France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.